Literature DB >> 15184887

Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.

Hesham M Amin1, Timothy J McDonnell, Yupo Ma, Quan Lin, Yasushi Fujio, Keita Kunisada, Vasiliki Leventaki, Pamela Das, George Z Rassidakis, Cathy Cutler, L Jeffrey Medeiros, Raymond Lai.   

Abstract

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK(+) ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK(+) ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK(+) ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705(tyrosine --> phenylalanine), a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G(1) cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184887     DOI: 10.1038/sj.onc.1207703

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

Review 1.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

2.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  STAT3: a multifaceted oncogene.

Authors:  David E Levy; Giorgio Inghirami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

4.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

5.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 6.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

7.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

8.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Authors:  Elisa Spaccarotella; Elisa Pellegrino; Manuela Ferracin; Cristina Ferreri; Giuditta Cuccuru; Cuiling Liu; Javeed Iqbal; Daniela Cantarella; Riccardo Taulli; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Massimo Negrini; Wing C Chan; Giorgio Inghirami; Roberto Piva
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

9.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.